TP53 and long COVID-19: Additional autoantibodies against immune cell surface receptors (IL7R, CD69), SARS-CoV-2 entry receptors (ACE2), thrombosis proteins (APOH, TFPI), and an apoptosis factor (TNFRSF11B) were increased in PASC participants at an FDR of 0.1, while autoantibodies against the tumor protein, p53, was increased in non-PASC participants (Figure 4A).